Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CVD 1208S, a Shigella flexneri 2a live, oral vaccine
BIOLOGICAL
2 trials
Sponsors
University of Maryland, Baltimore
Conditions
Shigella
Phase 1
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP
Completed
NCT01531530
University of Maryland, Baltimore
Shigella
Start: 2011-07-31
End: 2012-09-30
Updated: 2021-04-30
Phase 2
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa
Terminated
NCT00866476
University of Maryland, Baltimore
Shigella
Start: 2010-01-31
End: 2010-02-28
Updated: 2021-04-29
Related Papers
T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans.
2018-03-13
18 citations